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Summary 
Receptor protein tyrosine kinases  (RTKs)  transmit  downstream signals  via interactions with 
secondary signaling molecules containing SH2 domains. Although many SH2-phosphotyrosyl 
interactions have been defined in vitro, little is known about the physiological significance of 
specific RTK/SH2 interactions in vivo. Also, little is known about the mechanisms by which 
specific RTKs interact with and/or are regulated by specific protein tyrosine phosphatases  (PTPs). 
To address such issues, we carried out a genetic analysis of the previously reported biochem- 
ical interaction between the RTK c-Kit,  encoded at the  W locus,  and the  SH2-containing 
non-transmembrane PTP SHP1, encoded at the motheaten  (me) locus (1). Mice carrying a kinase- 
defective allele  of c-Kit (//l/v/+) were crossed with me/+  mice, which carry one effectively 
null allele ofSHP1, and then backcrossed to generate all possible allelic combinations. 
Our results indicate strong intergenic complementation between these loci in hematopoietic 
progenitor cells. Compared to progenitors purified from normal mice, bone marrow progeni- 
tor cells  (lin-)  from me~me mice markedly hyper-proliferated in response to Kit ligand  (KL) 
stimulation.  Superimposition of the me~me genotype increased the number of bone marrow- 
derived CFU-E from W'/+  mice. Conversely, the presence of one or two copies of//I/v de- 
creased the number ofmacrophages and granulocytes in me~me lung, skin, peripheral blood and 
bone marrow, thereby decreasing the severity of the me~me phenotype. The decrease in dermal 
mast cells in H/v/Vr  v mice was rescued to levels found in H/V/+ mice by superimposition of the 
me~me genotype. Surprisingly, however, the presence or absence of SHP1 had no effect on the 
proliferative response of bone marrow-derived cultured mast cells to KL or IL3 ex vivo. Nev- 
ertheless, the immediate-early response to KL stimulation, as measured by KL-induced tyrosyl 
phosphorylation, was substantially increased in mast cells from H/v/+ :me~me compared to  l/l/v/ 
+:+/+  mice, strongly suggesting that SHP1  directly dephosphorylates and  regulates c-Kit. 
Taken together, our results  establish  that  SHP1  negatively regulates signaling from c-Kit in 
vivo, but in a cell type-specific manner. 
T 
he phosphorylation of proteins on tyrosyl residues is a 
key mechanism for regulating proliferation and differ- 
entiation of hematopoietic cells.  The steady state level of 
phosphotyrosine on any protein is determined by the op- 
posing actions of protein tyrosine kinases  (PTKs) 1 and pro- 
1  Abbreviations used in this paper: BMCMC, bone marrow-derived  cultured 
mast cells; KL, Kit ligand; PTK, protein tyrosine  kinase; PTP, protein ty- 
rosine phosphatases; RTK, receptor  protein tyrosine  kinase; WBC, white 
blood count. 
tein tyrosine phosphatases  (PTPs). Two types of receptors 
evoke tyrosyl phosphorylation events to  transduce  signals 
generated by polypeptide growth  and  differentiation fac- 
tors. Many growth factors signal  via receptor tyrosine ki- 
nases  (RTKs)(2, 3), which possess intrinsic tyrosine kinase 
activity. In contrast, most cytokine receptors, such as the 
IL3 receptor, lack intrinsic enzymatic activity but associate 
with non-transmembrane (non-TM) PTKs (4, 5). 
Upon ligand binding, RTKs oligomerize, become acti- 
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Analogously, cytokine receptor stimulation leads to the ac- 
tivation of the  associated  non-TM  PTK(s),  which  phos- 
phorylate  themselves  and  the  cognate  receptor.  Down- 
stream  signals  from  RTKs  and  cytokine  receptors  are 
transmitted via interactions of receptor phosphotyrosyl res- 
idues with secondary signaling molecules containing SH2 
domains (6-8). 
Although  many  SH2-phosphotyrosyl interactions  have 
been  defined in  vitro  and  in  tissue  culture  cells  (i.e.,  ex 
vivo), little  is  known  about the  biological significance of 
these interactions in vivo. Experiments in lower eukaryotes 
provide the only clear examples in which the physiological 
importance of an interaction between a specific SH2-con- 
taining  protein  and  a  putative  phosphotyrosyl target  has 
been  established.  Molecular genetic  analysis  of the  let-23 
pathway in  C.  elegans indicated that sere-5, a Grb2 homo- 
logue, is required for activation of the ras homologue let-60 
(9).  Analogous  experiments  in  Drosophila  established  the 
importance of the sem-5/Grb2 homologue drk (10), as well 
as the guanine nucleotide exchange factor sos, in ras activa- 
tion by the sevehless  (11) and torso (12) RTKs. Similar pro- 
tein-protein interactions exist in mammalian cells, but the 
function(s) and importance of these complexes in specific 
cell types in vivo have not been established. 
Even less is  known  about  the  mechanism(s)  by which 
signals  induced by  growth  and  differentiation factors are 
terminated.  Dephosphorylation of phosphotyrosyl protein 
targets,  as well as  other mechanisms  such  as receptor en- 
docytosis, could play important roles in signal termination. 
However, the relative importance of such processes in ter- 
minating  specific signaling  pathways  is  largely undefined. 
Likewise,  for  those  pathways  in  which  tyrosyl  dephos- 
phorylation is believed to be important for negative regula- 
tion,  the  specific PTP(s)  that  control inactivation remain 
largely unidentified. 
We have evaluated the biological significance of the in- 
teraction between  a  specific  1KTK,  c-Kit,  and  a  specific 
PTP,  SHP1,  by  adopting  a  molecular  genetic  approach. 
The c-kit proto-oncogene encodes a classical 1KTK, which 
serves  as  the receptor for Kit ligand  (KL)  (also known  as 
Steel factor,  stem  cell factor,  or mast  cell growth  factor) 
(13-18). c-Kit function has been implicated in the prolifer- 
ation, survival, migration, and differentiation of germ cells, 
neural crest-derived cells  (e.g.,  melanocytes), and hemato- 
poietic stem cells,  as well as in cell type-specific functions 
(e.g.,  chemotaxis,  secretion)  in  more  differentiated  cells 
(19). SHP1 (20), formerly known as SHPTP1 (21), PTP1C 
(22), HCP (23), or SHP (24), is a non-transmembrane SH2 
domain-containing PTP expressed primarily in hematopoi- 
etic cells of all lineages and all stages of maturation. Previ- 
ous biochemical studies established that, after KL stimula- 
tion of factor-dependent Mo7e cells, SHP1 binds to tyrosyl 
phosphorylated c-Kit and itself becomes tyrosyl phosphor- 
ylated (1). Since SHP1 has been found to negatively regu- 
late  several  other  receptors  of the  hematopoietic  system 
(EPOR  [25],  IFN0~ [26],  TCIK [27,  28],  CSFllK [29]),  it 
seemed likely that it might be important for c-Kit inactiva- 
tion.  However, the functional significance of the c-Kit/ 
SHP1 interaction has not yet been established, either in cell 
lines or in whole animals. 
To assess the relevance of c-Kit/SHP1  interactions, we 
took advantage of mouse models of c-Kit and SHP1  defi- 
ciency. In mice,  c-Kit is  encoded at the  dominant  White 
Spotting (W) locus. Several different mutations affecting the 
c-kit gene have been described (30). Depending on the se- 
verity of c-Kit impairment caused by these mutations,  W 
mutant mice show varying degrees of several phenotypes: 
(a)  change  of black  coat color to  white because  of defi- 
ciency of neural crest cell migration, which results  in im- 
paired melanocyte development; (b) sterility; (c) macrocytic 
anemia resulting from decreased number of erythroid pro- 
genitor cells and impaired erythroid differentiation; and (d) 
deficient mast cell production in vivo and decreased or ab- 
sent  proliferation of bone  marrow-derived cultured mast 
cells in response to KL ex vivo. 
Mutations  at  the  SHP1  locus  cause  the  motheaten  (me) 
phenotype (31, 32). The me allele encodes a frameshift mu- 
tation  near  the  5'-end  of the  SHP1  coding  sequence, 
which results  in the  absence  of detectable SHP1  protein. 
Thus,  me~me mice are effectively SHP1  nulls.  These mice 
display a panoply of disorders affecting virtually all hemato- 
poietic lineages  and  die  within  two  to  three  weeks  after 
birth  (33).  Prominent  amongst  these  defects are  myeloid 
hyper-proliferation  and  inappropriate  activation,  which 
leads to the characteristic "motheaten" skin lesions and the 
interstitial  pneumonia  that  causes  their  early demise.  Al- 
though their erythroid progenitor cells (CFU-E) are intrin- 
sically  hyper-responsive  to  EPO  stimulation,  motheaten 
mice are anemic. Anemia in  me~me mice probably results 
from a combination of factors, including the displacement 
of erythroid progenitor cells from the bone marrow (to the 
spleen) as a consequence of the markedly expanded popu- 
lation of immature and mature myeloid cells (myelopthisis), 
as well as hypersplenism.  Coat color is normal in me~me 
mice, whereas the status  of mast cells has not been studied 
rigorously. 
We  examined the  effect of the  me~me  background  on 
c-Kit-responsive  cell  types  in  mice  bearing  normal  and 
White viable  (/d/v) c-Kit alleles,  as well as the effects of the 
Vr v mutation on several aspects of the me~me phenotype. To 
accomplish this, we crossed mice heterozygotic for me with 
mice  heterozygotic for  W'.  We  chose  the  V~  allele  be- 
cause, owing to a point mutation within its kinase domain, 
1~ has markedly diminished, but importantly, still detect- 
able c-Kit kinase activity (30, 34). We reasoned that if there 
were  a  biologically important  interaction  between  c-Kit 
and  SHP1,  mice  carrying mutations  at  both  loci  should 
manifest genetic interaction; i.e.,  Vv  v and me might exhibit 
intergenic  complementation.  We  found  that  c-Kit  and 
SHP1 do show genetic interaction, but in a tissue-restricted 
manner.  There was  strong intergenic complementation in 
the  hematopoietic  progenitor  cells  of  H/V/+:me/me  and 
VvV/ld/V:me/me  mice.  The  presence  of one  and  especially 
two copies of H/v decreases the severity of the me~me phe- 
notype, as manifested by fewer skin lesions and delayed on- 
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SHP1  improves ex vivo  erythropoiesis in the  H/v/+  back- 
ground, enhances the proliferative response of bone marrow- 
derived  progenitor  cells  to  KL,  and  increases  ("rescues") 
the  numbers  of dermal  mast  cells in  the  ears  of  W~/I4  ~v 
mice.  However,  we  detected  no  genetic  interaction  be- 
tween  H/v and me in the melanocyte lineage in vivo or in 
bone  marrow-derived  cultured  mast  cells  (BMCMC)  ex 
vivo.  Nevertheless,  biochemical  analysis  of  KL-induced 
signaling events  in BMCMC  from  mice  bearing different 
combinations of c-Kit and SHP1  alleles provides direct ev- 
idence  for  negative  regulation  of the  c-Kit  pathway  by 
SHP1.  Our  results  are  consistent with  a  model in  which 
SHP1  is  a  critical negative  regulator of c-Kit signaling in 
some, but not all, cell types. 
Materials  and Methods 
Mice.  F1  (combined heterozygotic VVV/+:me/+)  mice were 
generated  by  mating  heterozygotic  H/v/+  (C57BL/6J-lx  /4/v; 
Jackson  Labs,  Bar  Harbor,  ME)  with  heterozygotic  me/+ 
(C3HeB/FeJle-a/a-me; Jackson Labs, Bar Harbor, ME) mice. F2 
mice, carrying all possible combinations of mutations at the  W  ~ 
and  me loci, were generated by mating of combined heterozy- 
gotic mice.  Genotypes at  the  W locus were  identified by coat 
color,  whereas  genotypes at  the  me locus were  determined by 
polymerase chain reaction (PCR), using primers described previ- 
ously (31). Based on initial studies, which showed no differences 
between  +/+  and  me/+  mice,  both  were  used  as  "normal" 
controls,  indicated as  +/+(me).  14-18-d-old mice  were  used 
throughout the study. 
Primary BMCMC.  Mice  were  euthanized  by  inhalation  of 
CO2  before femurs  and  tibias were  flushed with  PBS  (8  mM 
Na2HPO4,  1.5  mM KH2PO4,  140  mM  NaC1,  3  mM KC1; pH 
7.4).  Bone marrow cells were washed twice with PBS and then 
resuspended  at  5  ￿  10s-5  ￿  106/ml  in  BMCMC  medium 
(RPMI-1640,  10% bovine calf serum, 15% WEHI 3-conditioned 
medium (source of IL3), 0.1 mM MEM non-essential amino acid 
solution (GIBCO BRL, Gaithersburg, MD), 2 mlVl L-glutamine, 
5  ￿  10 -s M  [3-mercaptoethanol, and antibiotics (Penicillin plus 
Streptomycin; GIBCO BRL). BMCMC were isolated by contin- 
uous transfer of  cells growing in suspension to new flasks for 4-6 wk. 
Homogeneity of BMCMC  was  confirmed by May-Gruenwald/ 
Giemsa staining (35). 
Histology and Morphometry.  Tissues from euthanized mice were 
fixed in 10% neutral-buffered formalin. Cardiac blood was taken 
immediately after  euthanasia  for  hematological analysis.  Tissue 
samples were embedded in paraffin, cut at 5 p-m, and stained with 
hematoxylin-eosin for histological evaluation. Samples of ear skin 
and  back  skin  were  obtained  and  processed for  1-p-m  Epon- 
embedded, Giemsa-stained sections (36, 37).  Sections were coded 
and then were examined by observers who were unaware of their 
identities. The number of mast cells per square millimeter of dermis 
in each specimen was determined as described previously (38, 39). 
Colony Forming Assays.  Femurs  were  flushed  with  RPMI- 
1640,  10% fetal bovine serum (FBS)(RPMI, 10%). Bone marrow 
cells were washed, resuspended in 10 ml RPMI, 10% per mouse, 
and twice plated for 1 h  at 37~  onto 100 mm plates to deplete 
adherent macrophages.  10  s non-adherent cells were resuspended 
in 3 rnl colony assay medium (IMDM [GIBCO BRL], 50% me- 
thyl cellulose, 25% FBS, 10% bovine serum albumin [BSA], 5  ￿ 
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10 -s  M  [3-mercaptoethanol,  2  U/ml  erythropoietin  [Amgen, 
Thousand Oaks, CA]), supplemented with the indicated concen- 
trations of KL (recombinant mouse KL; Genzyme, Boston, MA) 
or IL3 (BioSource International, Camarillo, CA). The cell mix- 
ture  was plated in three wells,  containing 1 ml each.  Colonies 
were scored after 6-7 d. Experiments shown represent one of at 
least three independent experiments. 
Purification of lin-  Bone Marrow Progenitor Cells and Flow Cyto- 
metric Analysis.  Bone  marrow  cells were purified and depleted 
of adherent macrophages as described above (see colony forming 
assays). Red blood cells were lysed for 5 rain on ice in 0.15  M 
NH4C1,  0.1  mM EDTA,  10 mM KHCO3.  The remaining cells 
were washed and resuspended in PBS, 2% FBS (1 ml/mouse) and 
0.2  p-g/106  cells of the following antibodies (all purchased from 
PharMingen,  San  Diego,  CA)  were  added for 20  min  on  ice: 
Ter119, CD4, CD8, B220,  GR1, Mac1. Cells were washed and 
1 ml/2.5 ￿  107 cells of sheep anti-rat IgG coupled to Dynabeads 
M450  (Dynal, Lake Success,  NY) was added for 20 rain at 4~ 
After two rounds of exposure to a magnetic field, lin- cells were 
isolated.  Lin-  bone  marrow  progenitor  cells  (2  ￿  105) were 
stained with anti-c-Kit antibody (CDl17),  precoupled to FITC 
(purchased from PharMingen), in PBS, 3% BSA and 0.1% sodium 
azide. Stained progenitor cells (5,000)  were analyzed by flow cy- 
tometry using a FACScan  |  instrument (Becton Dickinson, Bed- 
ford, MA). 
Proliferation Assays.  BMCMC  (2  ￿  104/we11/200  p,1  me- 
dium) or lin- bone marrow progenitor cells (1.4 X 10VweU/200  p-1 
medium) were plated in triplicate in BMCMC medium without 
WEHI 3-conditioned medium, supplemented with the indicated 
amount of KL or IL3 and incubated for 60  h.  They were then 
pulsed  with  1  p-Ci  of [3H]thymidine  for  4  h,  harvested,  and 
[3H]thymidine incorporation was measured using a cell-harvester 
(Skatron Instruments, Sterling, VA). 
Immunoprecipitations and Immunoblotting.  Cells lysates were pre- 
pared from primary human melanocytes (Clonetics) and from pri- 
mary BMCMC.  Some BMCMC  cultures were stimulated with 
KL (500 ng/2  X 107 cells/ml) for the indicated times before lysis. 
Cells (4  X  107/ml)  were lysed in NP-40 buffer (0.5%  Nonidet 
P-40  [NP-40],  150  mM  NaC1,  50  mM Tfis-HC1  [pH 7.6],  10 
mM sodium pyrophosphate, 1 mM Na3VOa,  10 mM NaF, leu- 
peptin [10  p,g/nil], aprotinin [1  p-g/roll, pepstatin A  [1  p-g/ml], 
antipain [1  p-g/re.l],  and phenylmethylsulfonyl fluoride  [20  p-g/ 
ml]).  Lysates  were  clarified by  centrifugation  for  20  min  at 
100,000 g at 4~  and immunoprecipitations with anti-phospho- 
tyrosine agarose (30 p-1 of 50% suspension PT66 coupled to aga- 
rose; Sigma Chem. Co., St. Louis, MO) or with anti-SHP1 anti- 
bodies (40) were performed on cleared lysates. Immune complexes 
were washed five times in NP-40  buffer.  Total cell lysates  and 
immune  complexes were  resolved by SDS-PAGE and  electro- 
blotted onto  Immobilon P.  Immunoblotting was  performed as 
described previously (40),  using the  following antibodies (with 
concentrations recommended by the manufacturers): monoclonal 
anti-SHP1  (Transduction Laboratories, Lexington, KY), mono- 
clonal anti-phosphotyrosine 4G10  (Upstate Biotechnology, Inc., 
Lake Placid, N.Y.), polyclonal anti-MAPK (generous gift of Dr. 
J. Blenis) and anti-phospho-specific MAPK (New England Biolabs; 
Beverly,  MA).  Immunoblots  were  developed  using  enhanced 
chemiluminescence (ECL; Amersham, Arlington Heights, IL). 
Results 
To examine the potential role of SHP1  in c-Kit signal- 
ing,  we  adopted  a  genetic  approach.  We  reasoned that if "Qx  Q 
I  I  J  I 
+/+  Wv/+  14~,/I~ 
Figure  1.  Schematic representation of strategy used to generate F I (/) 
and F2 (I/) mice with different combinations of mutations at W and me 
loci. The first ten litters showed the following distribution of F2 geno- 
types: 23 +/+:+/+(me);  9 +~+:me~me; 40 +/H/v:+/+(me); 13 +/V~: 
me~me; 15 Vcv/VvV:+  / +(me); 7 H/V/W':me/me. 
SHP1  negatively regulated  c-Kit in vivo, loss of SHP1  ac- 
tivity  (in  me/me mice)  might lead to  hyper-responsiveness 
of KL-sensitive cell types. Moreover, since  1/1/v  retains some 
kinase  activity,  superimposing  partial  or  complete  loss  of 
SHP1  (on  WV+  or  VVV/H/v  mice)  might  to  some  extent 
rescue defective c-Kit function.  Conversely, impaired c-Kit 
function  might  "normalize"  certain  aspects  of the  me~me 
phenotype. An in vivo approach also might have the advan- 
tage of revealing whether any of the  observed effects were 
cell type/tissue-specific.  Therefore,  we analyzed the prog- 
eny of crosses between  me/+  and  H/V/+  mice.  F1  double 
heterozygotic  mice  (l/l/V/+:me/+)  were  obtained  and 
crossed with each other to generate an F2 population with 
all nine  possible  genotypes  (Fig.  1),  which  resulted  in  six 
different phenotypes (see Materials and Methods). 
H/v Reduces  the Severity  of the me~me Phenotype,  but me~me 
Does  Not Alter the  Effect  of H/v on  Melanocyte  Development. 
All combinations of the two mutations were viable, and the 
F2 generation showed the expected distribution  of the dif- 
ferent genotypes  (Fig.  1).  The  presence  or absence  of the 
me allele had no obvious consequence  on the effects of the 
c-kit  locus  on  coat  color phenotype  (Fig.  2,  A-C).  Earlier 
studies  had  not  established  whether  SHP1  is  expressed  in 
normal neural crest-derived cell types, although it has been 
reported that SHP1  is expressed in PC12  cells,  a rat pheo- 
chromocytoma-derived  cell line  (41).  Consistent  with  the 
lack  of genetic  interaction  between  me  and  H/v for  coat 
color  determination,  immunoblotting  revealed  no  detect- 
able expression of SHPl  in primary melanocytes (Fig. 2 D). 
These  results suggest that SHP1  is not  a limiting  negative 
regulator  of c-Kit in  melanocytes  nor,  most likely,  in  less 
differentiated neural crest cells.  H/V/H/v and me~me mice are 
sterile. We did not address the question of whether  W'/H/V: 
me~me mice were  sterile  because  most  of these  mice  died 
prior to, or just at the time of, reaching sexual maturity. 
White  (i.e.,/~/Vr v) me~me mice appeared to have mark- 
edly fewer skin lesions  than  their black  (i.e.,  c-Kit  +/+) 
me~me littermates.  Moreover,  white  me~me mice  appeared 
healthier  at  younger  ages  (2-3  wk)  and  tended  to  live 
longer than their black me~me littermates. Although we did 
not maintain large numbers of VVV/H/V:me/me or +/+  :me~me 
mice  until  their  natural  deaths,  at  least  7  VvV/H/V:me/me 
lived 6-7 wk,  whereas  none  of the  +~+:me~me mice ob- 
tained  in  this  cross  or in  our  much larger  me/+  breeding 
stock  ever reached  this  age.  These  clinical/morphological 
observations  were  confirmed  by  histological  analysis.  At 
two to three weeks of age, me~me mice exhibited the char- 
acteristic  extensive  infiltrates  of granulocytes  and  macro- 
phages in their skin, whereas double homozygotic (H/V/H/V: 
me~me) mice had both markedly fewer and less severe der- 
mal lesions  (Fig.  3, A-H).  Similarly,  age-matched  Vvv/V~': 
me~me mice had minimal or absent myeloid cell infiltration 
in their lungs, resulting in less severe interstitial pneumonia 
than  was  exhibited  by  their  littermate  +~+:me~me  mice 
(Fig. 3,  G-H). 
SHP1 Negatively Regulates  c-Kit in Hematopoietic  Progenitor 
Cells.  The  results  described  above  suggested  that  a 
marked reduction  of c-Kit activity can reduce  the severity 
of the  me~me phenotype  in  vivo.  Further  support  for this 
conclusion  was  obtained  by  analysis  of peripheral  blood 
counts  (Table  1).  The  dramatically  elevated  white  blood 
count  (WBC)  in  me~me  mice  was  reduced  to  approxi- 
mately  normal  levels  in  VVV/VvV:me/me  or  H/V/+:me/me 
mice.  However,  the  macrocytic anemia caused by the  Vr v 
allele was not improved by loss of SHP1.  There are several 
possible reasons why loss of SHP1  might  not improve the 
anemia  of White viable mice:  (a)  SHP1  might  not  regulate 
c-Kit  signaling  in  erythroid  progenitor  cells;  (b)  SHP1 
might regulate  c-Kit in erythroid progenitor cells, but loss 
of SHP1  might not be sufficient to "rescue" the  W' muta- 
tion; or (c) SHP1 might regulate c-Kit in erythroid progenitor 
cells, but since me~me mice are themselves anemic, the com- 
bination of the  W v and me~me mutations might not result in 
restoration of a normal hemoglobin/hematocrit  (33, 42). 
To distinguish  between these possibilities,  we examined 
the  differentiation/proliferation  capacity of bone  marrow- 
derived  hematopoietic  progenitor  cells  in  a  more  con- 
trolled  environment  by using  ex vivo  colony forming  as- 
says. Macrophage-depleted bone marrow cells from normal 
and  me~me  mice  were  tested  for  their  abilities  to  form 
erythroid  (BFU-E)  and  myeloid  (CFU-GM)  colonies  in 
response  to increasing  amounts  of KL  (Fig.  4).  Compared 
to normal littermates, bone marrow from me~me mice gave 
rise  to  increased  numbers  of BFU-E  at  all  doses  of KL 
tested  (Fig.  4  A).  KL is  not  typically viewed  as  a  growth 
1114  Cell-type Specific Regulation of c-Kit by SHP1 Figure 2.  (A-C). Photographs ofF2 generation mice depicting the six skin and coat color phenotypes. (A) +/+:+/+ and +~+:me~me, (B) Vr 
and WV/+:me/me, (C)  H'v/V~:+/+ and  V~/l,  FV:me/me. (D) SHP1 is not expressed in melanocytes. SHP1 was immunoprecipitated from primary cul- 
tures of human dermal melanocytes (107)(Clonetics, San Francisco, CA) or LSTtKA cells (10v), which express abundant amounts of SHP1 (40). After 
SDS-PAGE (8% gel), SHP1 was detected by immunoblotting with anti-SHP1 antibodies. 
factor that directs myeloid cell differentiation. However, at 
high doses or in synergy with granulocyte macrophage-col- 
ony  stimulating  factor,  KL  can  stimulate  low  levels  of 
CFU-GM  production  (43).  In me~me mice, KL was more 
effective at promoting CFU-GM  (Fig. 4  B). Notably, if we 
extensively depleted the  large  excess  of macrophages  and 
other adherent ceils from the bone marrow of me~me mice, 
we did not observe significant numbers of either BFU-E or 
CFU-GM  in  the  absence  of added KL  (or  other  growth 
factors;  data not  shown),  arguing  that  hematopoietic pro- 
genitor  cells  from  me~me  mice,  like  those  from  normal 
mice, are not capable ofautocrine colony formation. 
Although  other  explanations are  not  formally excluded 
(see below),  these  data are  consistent with  the  hypothesis 
that  SHP1  negatively  regulates  c-Kit  signal  transduction 
pathway(s) that control erythropoiesis and that may poten- 
1115  Lorenz et al. tiate myelopoiesis. Further support for this notion was pro- 
vided by analysis of compound mutants. Bone marrow cells 
from  l&v/W  ~ mice could not be stimulated by KL to pro- 
duce  BFU-E  or CFU-GM  regardless  of the  alleles  at  the 
SHP1 locus.  However, a significantly increased number of 
KL-evoked BFU-E was obtained from H/v/+ :me~me, com- 
pared with  H/V/+:+/+(me) mice (Fig. 4  C). These results 
suggest that loss of SHP1 is not sufficient to rescue the vir- 
tually absent  kinase  activity of c-Kit in  H/V/I&  v mice,  but 
can increase significantly the effect of the residual c-Kit ac- 
tivity present in  l/V'/+ mice. 
Taken together with previous biochemical studies show- 
1116  Cell-type Specific Regulation of c-Kit by SHP1 Figure 3.  Sections of lung and skin of mice with different combinations of mutations at Wand me loci. A-F show sections of skin, G-L show sections 
of lung, stained with hematoxylin-eosin; bars =  115 la.m. (  A, G)  H,'v  / VvV:  + / + (me), (  B, H)  H/v/ + :  + / + (me), (  C, 1)  Vev  / W~ me  /me,  (  D, .])  +/+:+/+(me), 
(E, K)  +~+:me~me,  (F,  L)  H/v/ +:me/me.  (A-F) Skins from the  H/v/vcv:+ / +(me)(A),  Vc~/  +:+ / +(me)(B),  PV"/VCV:me/me  (C), and + / +:+ / +(me)(D) 
were normal. No histological alterations could be seen in the dermis (d) or subcutis (s), whereas the skins from the +~+:me~me (E), and V~/+:me/me (F) 
mice had a diffuse and locahzed inflammatory cell infiltration in the dermis and subcutis with a marked effacement of the dermal and subcutaneous archi- 
tecture. (G-L) Lungs from W~/H/v:+/+(me)(G), W~/+:+/+(me)(H),  H/V/H~:me/me  (1), and +/+:+/+(me)(J) were normal. No histological alterations 
could be seen in the alveolar parenchyma (p), around airways (a), or in blood vessels (v), whereas lungs from the +~+:me/me (K), and I~/+:me/me (L) 
mice had a diffuse inflammatory cell infiltration in the alveolar parenchyma, around airways, and in blood vessels, in particular in the +~+:me~me (K) 
mace. 
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Figure  4.  me~me mutation  increases colony-forming ability  of bone 
marrow-derived progenitor cells.  (A) Number of BFU-Es (in response to 
the indicated dose of KL) per  10  s plated bone marrow cells from +/+: 
+/+(me)  and +~+:me~me mice  (three  left pairs  of columns) and from 
Wv/V~:+/+(me)  and  H/v/Wqme/me  mice  (right  pair  of columns).  (B) 
Number of CFU-GMs (in response to the indicated dose of KL) per 10  s 
plated bone marrow cells from +/+:+/+(me) and +~+:me/me mice  (3 
left pairs of columns) and from W~/lip': + / + (me) and l/k"/W~: me~me mice 
(right  pair  of columns).  (C)  Number of BFU-Es per  10  ~ plated bone 
marrow  cells  from  W~/+:+/+(me) and  V~/+:me/me  mice.  Error  bars 
represent the standard error of the mean_ Where no error bars are visible, 
the error was smaller than the symbol for that point. 
ing that SHP1 binds directly to c-Kit, these genetic data are 
consistent with the hypothesis that SHP1  is a critical  nega- 
tive regulator of c-Kit signaling in hematopoeitic progeni- 
tor  cells.  However,  there  are  other  possibilities.  The  re- 
sponse  to  KL  is  dependent  on  the  level  of c-Kit  surface 
expression as well as its  enzymatic activity.  Therefore,  we 
investigated whether the me mutation affects  c-Kit expres- 
sion  levels.  Early  (lineage-negative,  lin-)  hematopoietic 
progenitor cells  from  normal  and  me~me  littermates  were 
isolated by negative selection  (see Materials  and Methods) 
and analyzed for c-Kit surface  expression by flow cytome- 
try.  Three  sub-populations  could  be  identified  based  on 
their relative c-Kit expression levels: c-Kit  neg, c-Kit  1~  and 
c-Kit  high (Fig.  5). Although there were no major differences 
in the level of c-Kit expression between normal and me~me 
bone marrow progenitor cells  (Table 2), there was a slight 
Table  1.  Hematological Parameters of Mice with Different Allelic  Combinations  at W  and me loci 
Genotype: c-kit:  + :+  + : +  H/v: +  VcV: +  I/~: 1/I/v  H/V: l&  v 
me  +:+ (me)  me:me  +: + (me)  me:me  +:+ (me)  me:me 
WBC  (￿  mm -3)  10.7  +  3.8  32.3  -+  13.6  7.2  +  2.8  15.6  ___ 2.3  8.8  +  3.6  12.0  -+  6.3 
1KBC (￿  10 -(' mm -3)  5.8  +  0.4  3.9  -+ 0.4  4.3  +  0.2  3.6  +  0.3  3.3  +  0.3  2.8  -+ 0.3 
Hgb (g/dl)  12.0  +  0.3  9.2  +  1.3  9.5  +  0.4  8.5  +_  0.4  8.6  _+  0.6  7.6  _+  0.6 
MCV  58.3  +  3.3  66.8  --- 3.9  63.7  +  2.0  69.4  +  3.1  76.3  +  2.6  74.3  -+ 6.6 
WBC, white blood count; 1KBC, red blood count; Hgb, hemoglobin concentration; MCV, mean corpuscular volume. 
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Figure  5.  Flow cytometric 
analysis of normal and  me~me 
lin-  bone  marrow progenitor 
cells. (A, B) Dot plots displaying 
forward versus side scatter oflin- 
bone  marrow progenitor  cells 
from normal (A) and me~me  (t3) 
mice. (C, D) Histograms of c-Kit 
surface expression of lin-  bone 
marrow  progenitor cells  from 
normal (C) and me~me  (i) mice. 
Thresholds used to  characterize 
c-Kit  "r  c-Kit  ~~  and  c-Kit  high 
are indicated. Percentages of re- 
spective subpopulations are listed 
in Table 2. 
increase  in the  relative  number of c-Kit  high cells  (14-21%) 
in me~me mice. 
It has been reported that lin-  c-Kit  high cells  are enriched 
for erythroid progenitor cells  (44). Although the increased 
percentage  of such  cells  in  me~me  mice  could  in  part  ac- 
count for the observed increase in BFU-Es, it is unlikely to 
account for the nearly ten-fold increase in BFU-E produc- 
tion in response to sub-saturating KL concentrations (Fig. 4 A; 
see  Discussion).  The  increased  number  of BFU-E  in  the 
presence of the me~me mutation also may be due to the hy- 
per-responsiveness  of one or more PTK pathways that act 
within  early hematopoeitic  progenitor cells to give rise to 
increased numbers of c-Kit-responsive cells.  Although flow 
cytometric analysis oflin- cells allowed us to determine re- 
liably the  relative  proportion of c-Kit-positive and -nega- 
tive  cells  (which is essentially the same in normal and  me/ 
me  mice),  this  analysis does not allow accurate  determina- 
tion of the absolute  number of c-Kit-positive  cells  in total 
bone marrow. Because lin- cells represent such a small per- 
centage of total bone marrow cells,  such an estimate would 
be prone to large errors. 
Therefore, we evaluated whether a given number oflin- 
cells  from me~me mice displayed increased sensitivity to KL 
compared with their normal littermates  (shown by flow cy- 
tometry to  contain  comparable  fractions  of c-Kit-positive 
cells)  by measuring their proliferative response to KL stim- 
ulation  (Fig.  6).  Progenitor cells from me~me  mice showed 
dramatic  hyper-proliferation  (50-60X)  in response  to KL 
stimulation.  Again,  this  substantially  increased  response 
cannot easily be explained solely by the ,'~  increase in 
c-Kit  high cells  (see  above, Table 2, and Discussion).  Instead, 
it  supports  the  hypothesis  that  SHP1  is  a  direct  negative 
regulator of c-Kit in hematopoietic progenitor cells. 
W'/W'Affects  Myelopoiesis  in me~me Mice.  We  observed 
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that  me~me  mice had a less severe  "motheaten" phenotype 
in  the  presence  of the  H/v/w  '  genotype  (Figs.  2  and  3). 
Hyper-proliferation of the myeloid lineage is thought to be 
one  of the  major problems  in  me~me  mice that  results  in 
their early death.  We reported in Table  1 that  W'/W' re- 
duced the peripheral  blood WBC of me~me  mice to values 
even lower  than  those  in  normal  (at  the  me  locus)  mice. 
We also assessed whether the presence of H/V/l/I  * could sup- 
press  increased  myelopoiesis  of me~me  bone  marrow pro- 
genitor cells  ex vivo. We  observed a  dramatic  increase  in 
the number of CFU-GM in + / +:me~me and 14a'/+ :me~me, 
compared with  + / +: + / + (me)  and  l/I/v/+: + / + (me)  mice, 
respectively  (Fig.  7).  However,  consistent  with  their  im- 
proved phenotype, the number of CFU-GMs was reduced 
to almost normal levels in  H/v/VvV:me/me  mice.  This result 
shows that c-Kit indeed contributes to the control of mye- 
loid progenitor cell numbers.  In addition,  further support- 
ing  the  hypothesis  that  SHP1  negatively  regulates  c-Kit 
function, these data suggest that deregulated (excessive)  c-Kit 
Table 2.  Surface Expression of c-Kit on lin- Bone Marrow 
Progenitor Ceils from Normal [+/+(me)]  and me~me Mice (two 
Individuals Each) as Determined by Flow Cytometry 
c_Kittow  *  c_Kithigh * 
normal 1  54%  14% 
normal 2  55%  14% 
me~me 1  52%  21% 
me~me 2  43%  21% 
*Thresholds for c-Kit  L~  and c-Kit high are as shown in Fig. 5. 0.01 
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Figure  6.  Hyper-proliferation 
of me~me bone marrow-derived 
progenitor  cells  in  response  to 
KL. Proliferative  responses to in- 
creasing amounts of KL as mea- 
sured by [SH]thymidine incorpo- 
ration  of  lin-  bone  marrow 
progenitor cells from normal (m) 
and  me~me (I)  mice.  Note  that 
scales  are  different  for  normal 
and  me~me proliferative  re- 
sponses. Proliferative  response  of 
nom~at progenitor cells is shown 
in the insert to elucidate  their re- 
sponsiveness  to  KL  stimulation. 
Error bars represent the standard 
error of the mean. Where no er- 
ror bars are visible, the error was 
smaller than the symbol  for that 
point. 
activity contributes  significantly to  the  generation  of the 
me~me phenotype (see Discussion). 
SHP1 Regulates  Tyrosine Phosphorylation  of c-Kit and Num- 
bers of Dermal Mast Cells in H/V/H/v Mice In  Vivo,  but not KL- 
induced BMCMC Proliferation Ex  Vivo.  Mice  carrying  one 
or  two  H/v  alleles  display  defective  mast  cell  production 
(19). This is reflected by diminished numbers of dermal mast 
cells in vivo and by severely impaired proliferation of BM- 
CMC  in response to KL ex vivo (35). Measurements of der- 
mal mast cell density in the back skins and ear skins of mice 
showed  that,  in the  absence of SHP1,  the  number  of der- 
mal mast cells,  particularly in the ears  of H/v/W  '  mice,  in- 
creased  (Table  3).  These  data  are  consistent with  the  hy- 
pothesis  that  loss  of the  negative  regulator  SHP1  permits 
the residual kinase activity of the kinase-defective c-Kit en- 
coded by the  Vv  v allele to rescue,  at least partially, the mast 
cell-deficiency of Wv/H/v mice. However,  it remained pos- 
sible  that  other  abnormalities  present  in  me~me mice,  but 
not  intrinsic  to  mast  cells  (e.g.,  over-production  or  inap- 
propriate  production  of other  cytokines  in  the  absence  of 
SHP1)  might have compensated for the deficient c-Kit ac- 
tivity in  H/v/W  ' mice. 
To assess c-Kit signaling intrinsic to mast cells, we inves- 
tigated whether  the  presence  or absence  of SHP1  affected 
the ability of BMCMC  to proliferate in response to KL.  In- 
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Figure 7.  /~' mutation attenuates increased granulopoiesis  observed in 
me~me mice. Number of CFU-GMs per 103 plated bone marrow cells in 
response  to saturating amounts of IL3  (10  ng/ml) from  +/+  (two left 
columns), Vcv/+ (two middle columns), and Vvv/t/P  ' (two right columns) 
mice. Error bars represent the standard error of the mean. Where no error 
bars are visible, the error was smaller than the symbol for that point. 
Table 3.  Mast Cell Density (Number of Mast Cells Per mm  2) of 
Mice Carrying Various Genotypes 
Genotype 
Tissue  c-Kit: SHP1  Mean +  SE  Statistics 
Back Skin  +/+:++(me)  48.40  +  11.05 
+~+:me~me  35.61  +  6.11  P  =  0.350 
Vff'/+:+/+(me)  44.94  +  7.34 
W'/+:me/me  28.32  +- 4.12  P  =  0.096 
Vvv/V~:+/+(me)  16.04  +  3.61 
Vff'/W~:me/me  21.50  +- 2.67  P  =  0.258 
Ear Skin  +/+:+/+(me)  77.14  +  5.97 
+~+:me~me  50.24  -+ 8.68  P  =  0.063 
W'/+:+/+(me)  51.62  -+  10.77 
VvV/+:me/me  53.01  +  7.83  P  =  0.920 
WV/Wv:+/+(me)  8.86  +-  1.02 
Vff'/I/V~:me/me  44.31  +  13.89  P  =  0.044 
1120  Cell-type Specific Regulation of c-Kit by SHP 1 Figure 8.  (A-C) Proliferative responses of normal (m and q) or me~me (l and n) BMCMC to IL3 (m and/) or KL (q and n) stimulation. BMCMC from 
(A) +/+:+/+(me) and +~+:me~me mice; (B) VvV+:+/+(me) and H/V/+:me/me mice; and (C)  Wc/Vv~':+/+(me) and W~/Vv':me/me mice.  Error bars 
represent the standard error of the mean. Where no error bars are visible, the error was smaller than the symbol for that point. (D) SHP1 is expressed in 
BMCMC. Total cellular lysates of BMCMC (2 ￿  10  ~') were analyzed for SHP1 expression by SDS-PAGE (8% gel) followed by immunoblotting with 
anti-SHP1. 
terestingly,  in  contrast  to  the  morphometric  analyses  of 
dermal mast cell production in vivo (see above and Table 3) 
and to the results of our assays of hematopoietic progenitor 
cells, there was no detectable  difference in KL-driven pro- 
liferation  (as  measured  by  [3H]thymidine  incorporation) 
between  normal  and  me~me  BMCMC  (Fig.  8,  A-C).  As 
expected,  l/I/v/+-derived  BMCMC  displayed  a  decreased 
proliferative  response  to  KL  compared  with  BMCMC 
derived  from  littermates  which  expressed  normal  c-Kit, 
whereas  Vvv/Vv  v BMCMC  were  completely unresponsive 
to KL. Again, however,  in five out of six mice,  complete 
loss of SHP1  expression had no demonstrable effect on the 
proliferative  response to KL. There  also was no difference 
in proliferation between normal and me~me mast cells in re- 
sponse to IL3 stimulation,  even though SHP1  has been re- 
ported  to  regulate  IL3-induced proliferation  in  the  DA-3 
myeloid cell line  (45).  Intriguingly, mast cells  grown from 
one  I4"V/H/V:me/me  mouse responded to a limited extent to 
KL (to a level comparable to the typical response of H/V/+ 
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mice), whereas the IL3 response of these cells was unaltered 
(data  not  shown).  The  reason  for  this  discrepancy  is  not 
clear, but these findings raise the possibility that a third lo- 
cus may influence  the ability of SHP1  to regulate  c-Kit in 
mast cells  (see Discussion). 
Our results suggest that SHP1, at least with respect to the 
effects of  KL or IL3 on proliferation, is not a limiting nega- 
tive regulator (for c-Kit or the IL3 receptor)  in BMCMC. 
However,  unlike  in  melanocytes,  SHP1  is  expressed  in 
such cells  (Fig. 8 D). Even though SHP1 did not detectably 
influence  KL-induced  proliferation  in  BMCMC,  we  ex- 
amined  whether  immediate-early  signaling  events  stimu- 
lated  by KL binding,  such  as  tyrosyl phosphorylation  and 
MAP kinase  (MAPK)  activation  (46),  still  might be influ- 
enced by SHP1.  BMCMC  were  stimulated  with  KL, and 
total tyrosyl phosphorylation was analyzed by immunopre- 
cipitation  with  anti-phosphotyrosine  antibodies  followed 
by  anti-phosphotyrosyl  immunoblotting  (Fig.  9  A).  KL- 
stimulated BMCMC  showed a rapid increase in protein ty- Figure 9.  me~me  mutation improves the immedi- 
ate-early KL  response of BMCMC  from  I/V'/+ 
mice, as measured by KL-induced tyrosyl  phospho- 
rylation, but does not affect MAP-kinase activation. 
BMCMC from mice of the indicated phenotypes 
were stimulated for 0, 5, and 30 min with KL. (A) 
Lysates from KL-stimulated BMCMC  (2  ￿  107) 
were  imnmunoprecipitated with  anti-phosphoty- 
rosine antibodies and, after separation by  SDS- 
PAGE (8%), immunoblotted with anti-phosphoty- 
rosine. Note  that the  top  tyrosyl phosphorylated 
band in  IMTW'  BMCMC  is a background, non- 
specific band, not  c-Kit, which  is  not  tyrosyl 
phosphorylated in such cells. (B and C) Total cellu- 
lar  lysates (2  ￿  10  ~')  of the  same KL-stimulated 
BMCMC  as  used in  A were  analyzed by  SDS- 
PAGE (8%  gel) and  immunoblotting with anti- 
phospho-MAP-kinase (/3) or anti-MAP-kinase (C). 
rosyl phosphorylation. Most prominent amongst these phos- 
photyrosyt proteins was an ~,,150-kD species, which is c-Kit 
itself.  As expected,  H/v/+ BMCMC  also responded to KL, 
although  the  magnitude  of the  response  was  significantly 
reduced,  whereas  W~/H/v  BMCMC  were  unresponsive. 
We were unable to obtain sufficient quantities of  BMCMC 
from +~+:me~me mice to allow biochemical analysis. The 
non-responsiveness  of H/V/kl/v BMCMC  could not be res- 
cued by me~me, but in  I&v/+ BMCMC,  increased tyrosyl 
phosphorylation in the presence of the me~me mutation was 
observed  repeatedly.  Notably,  c-Kit  phosphorylation  was 
increased  significantly  in  the  me~me background,  showing 
levels  of phosphorylation equal  to or higher  than  c-Kit in 
normal  BMCMC.  The  increased  tyrosyl phosphorylation 
of  l/l/V/+:me/me  compared  with  H/v/+:+/+(me)  mice 
provides  direct biochemical  evidence  that  SHP1  regulates 
c-Kit  tyrosyl  phosphorylation  ex  vivo.  However,  SHP1 
regulation of c-Kit clearly is not limiting for the control of 
KL-driven proliferation  under  these  conditions.  (see  Dis- 
cussion). 
By  assaying  MAPK  activation  using  activation-specific 
antibodies,  we then determined whether the differences in 
KL-induced  tyrosyl phosphorylation  translated into  alter- 
ation of a downstream component of the c-Kit signaling path- 
way  (Fig.  9  B).  Interestingly,  there  was no  significant dif- 
ference  in  MAPK  activation  between  stimulated  normal 
and me~me mast cells. These results are consistent with SHP1 
not  being  a  limiting  negative  regulator  of KL-induced 
BMCMC  proliferation ex vivo. 
Discussion 
Our combined results  reveal two types of genetic inter- 
action between the RTK c-Kit and the PTP SHPI: (a) im- 
provement  of the  motheaten phenotype  upon reduction  of 
c-Kit activity, and  (b)  cell-type specific regulation of c-Kit 
activity  by  SHP1.  Together  with  previous  biochemical 
analyses  (1),  as well  as  our biochemical  studies  of the  im- 
mediate-early responses  to KL in BMCMC  (Fig.  9),  these 
results strongly suggest that SHP1  is a critical negative reg- 
ulator of c-Kit signaling in some, but not all, KL-responsive 
cell types.  Moreover,  our data suggest that dysregulation of 
c-Kit signaling pathways in hematopoietic  progenitor  cells 
may play an important role in the development of the me~me 
phenotype.  These  results  constitute  the  first  genetic  dem- 
onstrations  in  a  mammalian  system of the  biological  rele- 
vance of a biochemical  interaction  between  a RTK  and  a 
given  SH2-containing  protein  and  between  an  RTK  and 
its specific regulatory PTP. 
F2  double  homozygotic mice  (Vvv/WV:me/me)  appeared 
healthier than "c-Kit normal" motheaten mice (+ / +: me/me). 
This  was  confimled  histologically  by  the  finding  of de- 
creased numbers  of myeloid cells  infiltrating the lungs and 
skin, by the restoration of almost normal numbers of WBC 
1122  Cell-type  Specific Regulation of c-Kit by SHP 1 in the blood,  and by ex vivo colony forming assays, which 
revealed  a  decreased  number  of  bone  marrow-derived 
CFU-GM.  We  interpret  these  results  to  mean  that  im- 
paired  c-Kit  activity  decreases  the  generation  of hemato- 
poietic  progenitor  cells,  which  limits  the  myeloid  expan- 
sion  usually  observed in  me~me mice.  Although  KL is not 
generally viewed as a myeloid growth factor, high levels of 
KL can support  CFU-GM  generation  (Fig.  4  B  and refer- 
ence 47). In the absence of SHPl  (i.e., in me~me mice), hy- 
per-activation of c-Kit may contribute  directly to the gen- 
eration  of the  me~me phenotype by increasing the  number 
ofmyeloid progenitor cells. These results raise the interest- 
ing possibility that pharmacological inhibition  of SHP1  ac- 
tivity ex vivo  (for example,  in human  bone  marrow stem 
cell cultures)  might help to promote progenitor cell expan- 
sion. 
Genetic  interaction  between  c-Kit and SHP1  could oc- 
cur  in  two  general  ways.  c-Kit could  act primarily  on  an 
early  progenitor  cell(s),  in  which  SHP1  does  not  act, 
whereas  SHP1  controls  signaling pathways in more differ- 
entiated  cells.  With  substantially  reduced  c-Kit  signaling 
(i.e., in  W'/I/I/v mice), far fewer early progenitors would be 
produced,  thus  limiting  the  myeloid  expansion  caused by 
the loss of SHP1. Alternatively,  SHP1  could regulate c-Kit 
in the same (early progenitor)  cell,  as well as possibly con- 
trolling several signaling pathways in later cell populations. 
We  favor  the  latter  explanation,  in  view  of:  (a)  the  bio- 
chemical data demonstrating a physical interaction between 
SHP1  and  c-Kit in  Mo-7e  (1),  a  cell line  derived  from a 
relatively undifferentiated  cell  (48);  (b)  our direct  demon- 
stration  that  lin-  c-Kit +  progenitor  ceils  are  dramatically 
hyper-responsive to KL stimulation  ex vivo (Fig. 6), which 
argues  that  absence  of SHP1  leads  to  hyper-sensitivity  of 
c-Kit; and  (c) our demonstration  that the absence of SHP1 
in BMCMC  leads  to enhanced  c-Kit and  total cellular ty- 
rosyl phosphorylation  (Fig. 9 A). 
However,  the  influence  of SHP1  on  c-Kit  is  complex 
and cell type-specific. This is perhaps not totally surprising, 
since  the  quantitative  requirements  for various  cellular re- 
sponses to KL (e.g., proliferation,  suppression  of apoptosis, 
etc.)  are different.  Nevertheless,  our results  emphasize  the 
importance of the specific cellular context in which a given 
SH2/phosphotyrosyl  protein  interaction  occurs  in  deter- 
mining the biological relevance of that interaction.  For ex- 
ample,  coat  color,  which  is  controlled  by  neural  crest- 
derived cells, is not detectably affected by SHP1  status (Fig. 
2).  SHP1  is not  expressed  detectably  in  cultured  melano- 
cytes  (Fig.  2  D).  We  did  not  assess  SHP1  expression  in 
neural crest primordia, but we suspect that SHP1  is not ex- 
pressed  in  these  cells  either.  Most  likely  c-Kit signaling  is 
regulated by other PTPs and/or by other mechanisms (e.g., 
receptor modulation)  in neural crest cells. 
The  macrocytic  anemia  observed  in  mice  expressing 
(the)  1/1/v  allele(s) also is unaffected by loss of SHP1. Never- 
theless, ex vivo analysis of ceils derived from single or dou- 
ble mutant  mice indicates  a critical role for SHP1  in regu- 
lating  c-Kit function  in  erythroid  progenitor  cells.  In  the 
absence  of SHP1  the  number  of KL-induced  BFU-E  in- 
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creased in  cells derived from  +/+  or  H/V/+  mice.  How- 
ever, no response could be evoked in  H/v/Vr  v cells, indicat- 
ing  that  absence  of SHP1  can  up-regulate  a  KL-driven 
response  but  requires  a  minimal  amount  of c-Kit activity 
for  such  enhancement  to  be  physiologically  significant. 
This  rather  complicated  result  could  reflect  a  number  of 
possibilities:  (a)  the level of c-Kit surface expression  could 
be dependent  on SHP1  expression and higher levels of ex- 
pression  could  result  in  an  increased  response  to  KL;  (b) 
there could be an increased number oferythroid progenitor 
cells  because  loss  of SHP1  affects  some  other  pathway(s) 
earlier in development  (this  could be a pathway involving 
c-Kit  or  a  completely  different  pathway);  and/or  (c)  a 
higher  percentage  of progenitor  cells  responds  to  a  given 
amount  of KL  due  to  the  loss  of SHP1,  which  normally 
negatively regulates c-Kit activity. 
More than one of these explanations may apply. A  com- 
parable percentage of cells expressing low to medium levels 
of c-Kit was observed in/in-  cells isolated from both types 
of  mice;  however  me~me  progenitor  cells  displayed  an 
~50%  increase  in  the  proportion  of cells  expressing  high 
levels of c-Kit (Table 2).  Given the report that Kit  high cells 
are  enriched  for erythroid  progenitors  (44),  the  increased 
percentage  of such  cells could account,  at least in part, for 
the  increased  number of BFU-Es  observed in  me~me mice 
(42).  This  50% increase in the percentage  of c-Kit  high pro- 
genitor cells also could account for much (if not all)  of the 
,'-,1.5-fold increase in BFU-E  observed at saturating levels 
of KL.  However,  it  is  highly  unlikely  that  this  relatively 
small increase in the percentage of c-Kit  high progenitor cells 
could  account  for  the  10-15-fold  increase  in  BFU-Es  in 
me~me mice observed at sub-saturating levels of KL (Fig. 4 A). 
Flow cytometric analysis only indicates the relative levels of 
c-Kit expressing cells. Due to the very small percentage  of 
lin-  cells in the bone marrow (<1%),  such analyses cannot 
yield accurate estimates of the absolute numbers of progen- 
itor cells. Therefore, we measured directly the proliferative 
response of purified lin-  bone  marrow cells to KL. Under 
these  conditions,  in which  we knew,  on the  basis of flow 
cytometric  analysis,  that  approximately  equal  numbers  of 
c-Kit-expressing cells were being compared, fin- cells from 
me~me  mice  proliferated  50-60-fold  more  than  did  their 
normal counterparts.  Even though there probably are more 
KL-responsive progenitor cells in me~me mice than in nor- 
mal  mice,  it  is  clear  that  me~me  cells  also  are  intrinsically 
more responsive  to  KL stimulation.  These  results  strongly 
support  the  hypothesis  that  SHP1  acts  directly  on  c-Kit 
(within  the  same  cell),  thereby  controlling  c-Kit  activity 
and/or  the  phosphorylation  of c-Kit  targets.  Indeed,  the 
increase  in  c-Kit  high  cells  observed  in  me~me  mice  most 
likely is a consequence  of loss of SHPl  activity in the c-Kit 
pathway  in  vivo.  However,  we  cannot  exclude  formally 
the  unlikely  possibility  that,  due  to  the  absence  of SHP1, 
progenitor cells from me~me mice are predisposed to hyper- 
react to KL stimulation by a mechanism independent  of the 
direct interaction between c-Kit and SHP1. 
Although SHP1  regulation  of c-Kit appears to be critical 
in KL-responsive progenitor  cells,  it is not limiting  in  the more differentiated mast cell population,  l/I/v/+  and espe- 
cially  H/v/IV  ' mice exhibit a diminished number of tissue 
mast cells in vivo. We had anticipated that the absence of 
SHP1 might result in an effective increase in c-Kit-derived 
signaling  in  I/V'/+  and/or  VcV/H/v mice,  with  a  corre- 
sponding increase  in  mast cell number.  Indeed,  morpho- 
metric analysis of the number of dermal mast cells revealed 
that in the ear skin, loss of SHP1  did "rescue" the number 
of dermal  mast  cells  of I/V'/W' mice  to  levels  similar to 
those  observed in  H/V/+  mice  (Table  3).  In contrast,  we 
did  not  detect  any influence  of loss  of SHP1  on  dermal 
mast cell number in  the  back skin.  This could be due  to 
differences in  the  properties  of the  mast cells  (e.g..,  their 
sensitivity  to  changes  in  c-Kit  activity)  or  differences  in 
their origin and/or differentiation pathway. Loss of SHP1 
could influence the number of dermal mast cells in the ear 
by effects on cells early in the mast cell differentiation path- 
way, e.g., by generating more mast cell progenitors, and/or 
by affecting later stages  of differentiation  and  influencing 
viability and thereby life span of mature mast cells.  There- 
fore, we analyzed the effects of I/I/v  and me mutations on the 
proliferative  capacity  of BMCMC,  a  lineage-committed 
population of immature mast cells  (49,  50),  in response to 
KL.  In  all  H/V/+:me/me  and nearly all  (5/6)  VVV/l/VV:me/me 
BMCMC cultures tested, the absence of SHP1  did not af- 
fect KL-induced proliferation detectably. These results sug- 
gest that SHPI regulates dermal mast cell generation at an 
earlier  stage  of differentiation  or  by  effects  on  processes 
other than proliferation, or that SHP1  is limiting for c-Kit 
regulation  only in selected mast cell subpopulations  (e.g., 
dermal mast cells,  but not BMCMC).  Interestingly, how- 
ever, a BMCMC  culture  derived from one  l~/14"V:me/me 
mouse  did  proliferate  significantly  in  response  to  KL, 
whereas  all  of  the  14"~/H&+/+(me)  BMCMC  cultures 
tested were wholly non-responsive. Since the parental W'/+ 
and me/+ mice in our cross were of different genetic back- 
grounds (see Materials and Methods), a third, stochastically 
segregating locus could play a role in negative regulation of 
c-Kit, 
IL3-directed proliferation of BMCMC  also  is indepen- 
dent of SHP1  genotype (Fig.  8, A-C). Previous studies, in 
which antisense SHP1  IKNA was expressed in DA-3 cells, 
revealed an inverse correlation between lack of SHP1  ex- 
pression  and  IL3-driven proliferative response  (45).  Like- 
wise,  our results  (Fig.  7  and data not shown)  suggest that 
me~me bone marrow progenitor cells,  as well as bone mar- 
row-derived macrophages (Chen,  H., and B.G. Neel,  un- 
published observations) are hyper-sensitive to growth fac- 
tors  (1L3, GM-CSF)  that signal through  the common IL3 
receptor beta chain.  Together with  our KL/c-Kit results, 
these  data suggest that hematopoietic progenitor cells  and 
BMCMC may have distinctly different mechanisms of ter- 
minating  1KTK  and  cytokine  receptor-generated  signals. 
Loss  of SHP1  also  might  influence  KL-  or  1L3-induced 
pathways other than proliferation (e.g., potentiation of de- 
granulation, chemotaxis) in BMCMC. 
Although SHP1  is not limiting for KL-driven prolifera- 
tion in BMCMC,  biochemical analysis  of these cells  indi- 
cates  clearly that  SHP1  contributes  to  the  inactivation  of 
KL-initiated signals.  Superimposition of the  me~me geno- 
type resulted in substantial recovery of KL-induced tyrosyl 
phosphorylation in  the  VvV/+ background,  although  W'/ 
Vr  v BMCMC could not be "rescued" (Fig.  9 A). These re- 
sults  provide  direct  biochemical validation  of the  genetic 
interaction  between  c-Kit  and  SHP1.  Since  the  tyrosyl 
phosphorylation  of c-Kit is  modulated  by  SHP1  expres- 
sion, and SHP1 binds directly to c-Kit (1), our data suggest 
that c-Kit may be a direct target of SHP1. Despite the vir- 
tually  complete recovery of KL-induced tyrosyl phosphory- 
lation  in  VV'/+:me/me  BMCMC,  normal  KL-induced 
MAPK activation was not restored. This result parallels  the 
lack of effect of SHP1  loss on KL-induced proliferation of 
H/V/+  BMCMC.  There  are  several possible  explanations 
for this apparent discrepancy: (a) In addition to its negative 
regulatory role in the c-Kit pathway, SHP1 may also have a 
positive signaling function  upstream of MAPK,  such  that 
loss of SHP1 restores immediate-early tyrosyl phosphoryla- 
tion  events,  but not  MAPK  activation;  (b)  although  total 
tyrosyl  phosphorylation  is  restored  to  apparently  normal 
levels  in  VvV/+:me/me  mice,  subtle  differences  in  either 
specific c-Kit targets and/or in the kinetics of c-Kit tyrosyl 
phosphorylation may have been  missed by our assays;  (c) 
the  W  ~ mutation may be impaired in another c-Kit func- 
tion (e.g., endocytosis) important for downstream signaling 
and independent  of its impaired PTK activity; and/or  (iv) 
SHP1 may only dephosphorylate certain sites on c-Kit and/or 
certain  downstream  targets  of c-Kit,  whose  phosphoryla- 
tion  cannot  be  restored  to  normal  simply by the  loss  of 
SHP1. We suspect that SHP1 exerts similar biochemical ef- 
fects on c-Kit-induced tyrosyl phosphorylation in hemato- 
poietic progenitor cells,  but that either the absence of sec- 
ondary pathways of c-Kit inactivation and/or differences in 
the details of c-Kit-induced proliferative pathways in such 
cells results in a significant increase in KL-induced effects in 
the absence of SHP1.  The difficulty in obtaining sufficient 
numbers  of lin-  Kit +  cells  for biochemical analysis  limits 
our ability easily to resolve these issues.  Further studies will 
be required to elucidate the molecular explanation for tis- 
sue specific regulation of c-Kit by SHPI. 
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